RxDoctor Payments Data

Johnny Wu, MD

Internal Medicine · Fullerton, CANPI 1801356290

Payments from drug & device makers

$666in general payments, 2019–2025

Across 30 payments — averaging $22.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$446
  • Pfizer$78
  • Boehringer Ingelheim$44
  • Lilly USA, LLC$40
  • AstraZeneca$24
  • Scilex Pharmaceuticals Inc.$17
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$666100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$666 in reported general payments places this provider in the 70th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$138,776
Medicare patients
401
Services billed
1,474

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban111$128,243
JardianceEmpagliflozin61$92,873
OzempicSemaglutide59$59,263
MounjaroTirzepatide46$49,151
JanuviaSitagliptin Phosphate25$39,036
TrulicityDulaglutide20$24,532
XareltoRivaroxaban20$20,915
MyrbetriqMirabegron19$19,038
Repatha SureclickEvolocumab19$15,721
FarxigaDapagliflozin Propanediol18$14,768
Spiriva HandihalerTiotropium Bromide17$11,873
Stiolto RespimatTiotropium Br/Olodaterol Hcl15$11,488
Atorvastatin Calcium410$4,937
Rosuvastatin Calcium202$3,958
Levothyroxine Sodium192$3,010

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$78$128,243111 claims
Boehringer IngelheimJardiance, Stiolto Respimat$44$104,36076 claims
Lilly USA, LLCMounjaro, Trulicity$40$73,68366 claims
AstraZenecaFarxiga$24$14,76818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Fullerton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →